ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0078

Inhibition of the Deubiquitinase TRABID in a Pre-clinical Mouse Model of Axial Spondyloarthritis Decreases Disease Severity

Archita Srinath1, Daniele Mauro2, Mariia Korshko3, Shaghayegh Foroozan4, Mansi Aparnathi5, Francesco Ciccia6 and Nigil Haroon7, 1University of Toronto, Toronto, ON, Canada, 2University of Campania, Italy, Naples, Naples, Italy, 3University Health Network, Toronto, ON, Canada, 4University Health Network/University of Toronto, Toronto, ON, Canada, 5University Health Network, Toronto, Canada, 6University of Campania, Naples, Italy, 7Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada

Meeting: ACR Convergence 2024

Keywords: Animal Model, Ankylosing spondylitis (AS), immunology, Mouse Models, Other, Spondyloarthropathies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: SpA Including PsA – Basic Science Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Axial Spondyloarthritis is characterized by both inflammation and new bone formation. Current therapeutic targets aim to control inflammation, however, over 40% of patients do not respond to them. The novel deubiquitinase molecule TRABID has been shown to epigenetically control the expression of IL12/23 in the experimental autoimmune encephalomyelitis mouse model. Furthermore, our group has previously shown significantly increased expression of TRABID in human AxSpA tissues. We have also shown that the inhibition of TRABID in monocyte and osteoblast cell culture models significantly suppresses cytokine production and bone mineralization respectively. Therefore, this study aims to understand the in-vivo therapeutic potential of TRABID inhibition by the small molecule inhibitor NSC112200 in the SKG pre-clinical mouse model of AxSpA.

Methods: 8-week-old SKG mice were injected with the disease-causing agent curdlan or a PBS control. 8 weeks after disease induction, mice were sacrificed, and their tissues were harvested. Immunohistochemistry was used to determine the expression of TRABID in the affected joints (ankle and tail). Immune cells from the spleen were also harvested and incubated with the TRABID small molecule inhibitor NSC112200 and lipopolysaccharide to induce cytokine production for 24 hours. ELISA was then used to determine the production of TNFa in the cell culture supernatant. Finally, we wanted to determine if inhibiting TRABID in-vivo could be potentially therapeutic. 8-week-old SKG mice were injected with curdlan and 3 doses of NSC112200 at varying intervals for 8 weeks: low-dose (150mM/kg body weight every 2 days), mid-dose (300mM/kg every 5 days) and high-dose (300mM/kg every 2 days). Arthritis severity was scored every week. 8 weeks after disease induction, mice were sacrificed and tissues were harvested for histopathological analysis, nanostring immunology profiling and immunohistochemistry.

Results: TRABID was significantly upregulated in curdlan disease-induced mice (n=6) in the ankle (p=0.02) and tail (p=0.02) compared to controls (n=3). Moreover, splenocytes incubated with NSC112200 showed a marked dose-dependent decrease in TNFa production (p< 0.0001). Finally, after 8 weeks of treatment with NSC112200 at the 3 indicated doses, mice showed a dose dependant decrease in disease severity (p< 0.0001), including symptoms of blepharitis, paw swelling and psoriasis of the ears, snout and tail (Figure 1). Additionally, histopathological analysis of the ankle and tail showed decreases in immune infiltrate in the bone marrow, synovium and Achilles tendon, and decreased nucleus pulposus degeneration in the tail spine (p=0.023).

Conclusion: All together our data suggests that increased TRABID expression contributes to the pathology of disease in curdlan-treated SKG mice. Inhibiting the function of TRABID using NSC112200 showed therapeutic potential in these mice by possibly controlling the expression of key disease-causing cytokines such as TNFa. While the exact cellular and genetic targets of this inhibition are currently under exploration, this data provides early proof for a novel therapeutic target that can be blocked to control inflammation. 

Supporting image 1

Figure 1: Weekly clinical scoring of arthritis severity for 8 weeks after curdlan injection and NSC112200 administration (n=3 mice/group). The black line indicates the highest dose of NSC112200 administered which shows significant supression of arthritis severity compared to mice treated with curdlan alone (blue line). Doses are indicated as a function of body weight (i.e. 150mM/kg body weight).


Disclosures: A. Srinath: None; D. Mauro: AstraZeneca, 1, 6, GlaxoSmithKlein(GSK), 6, Janssen, 6, Novartis, 6, UCB, 6; M. Korshko: None; S. Foroozan: None; M. Aparnathi: None; F. Ciccia: None; N. Haroon: AbbVie, 2, Novartis, 2, UCB Pharma, 2.

To cite this abstract in AMA style:

Srinath A, Mauro D, Korshko M, Foroozan S, Aparnathi M, Ciccia F, Haroon N. Inhibition of the Deubiquitinase TRABID in a Pre-clinical Mouse Model of Axial Spondyloarthritis Decreases Disease Severity [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/inhibition-of-the-deubiquitinase-trabid-in-a-pre-clinical-mouse-model-of-axial-spondyloarthritis-decreases-disease-severity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inhibition-of-the-deubiquitinase-trabid-in-a-pre-clinical-mouse-model-of-axial-spondyloarthritis-decreases-disease-severity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology